Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $2.22 ($27K) on 2014-12-04, disclosed to the SEC on 2014-12-05.
Scheduled sale ($27k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.22 | 200 | $444 | 1.7% |
| 2 | $2.23 | 600 | $1K | 5.0% |
| 3 | $2.23 | 5,400 | $12K | 44.9% |
| 4 | $2.24 | 300 | $672 | 2.5% |
| 5 | $2.24 | 3,900 | $9K | 32.6% |
| 6 | $2.25 | 1,200 |
| $3K |
| 10.1% |
| 7 | $2.25 | 400 | $900 | 3.4% |
| Total | $2.24 avg | 12,000 | $27K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |